Health & Wellbeing
GBR | Jul 5, 2022

Scientists hope new test can help detect prostate cancer in black men

/ Our Today

administrator
In some countries such as Britain, black patients are twice as likely to develop prostate cancer and die of it than white men.

London (PA Media/dpa)

More must be done to reduce the “staggering racial differences” in prostate cancer, one expert has said as researchers set out to discover whether a tailored genetic test could spot the disease among black men.

Scientists are hoping to develop a new test using DNA information and AI technology to help improve detection of the disease among black men, who are twice as likely to get prostate cancer compared to white men in some countries.

The team, from Britain’s University of East Anglia (UEA), Imperial College NHS Healthcare Trust and Oxford Biodynamics, previously discovered that prostate cancer tumours leave a genetic imprint on blood cells.

RACIAL DISPARITY IN PROSTATE CANCER

They hope to look for specific genetic markers in the blood of black patients and compare them to white patients and a control group without cancer.

“In the UK there is a racial disparity in prostate cancer, where black patients are twice as likely to develop the disease and die of it than white men,” Prof Dmitry Pshezhetskiy, from UEA’s Norwich Medical School, said.

“Developing tailored genetic testing is really important because getting an early diagnosis allows better treatment. The five-year survival rate for men diagnosed with stage one prostate cancer is 100 per cent, compared with only 50 per cent for those with stage four cancer.”

Prof Dmitry Pshezhetskiy, from UEA’s Norwich Medical School

“Recent research shows that this staggering racial difference for prostate cancer diagnosis and mortality is due to genetic differences, but their exact nature is currently not known,” he said.

Pshezhetskiy said the goal was to create a fundamentally new, highly accurate genetic blood test for prostate cancer in black men, taking into account their genetic diversity.

“Developing tailored genetic testing is really important because getting an early diagnosis allows better treatment. The five-year survival rate for men diagnosed with stage one prostate cancer is 100 per cent, compared with only 50 per cent for those with stage four cancer.”

REAL POTENTIAL IN TARGETED GENETIC TEST

The UK institute Prostate Cancer Research, which is funding the work, said that there is “real potential” in the development of targeted genetic testing for the disease.

“There is a real need for a new way to diagnose prostate cancer, as the PSA blood test we currently use is not as accurate as we want, rectal exams are invasive and people understandably are not comfortable with them, and imaging techniques such as MRI require specialist equipment that may not always be available,” Dr Naomi Elster, director of research at the charity, said.

“We see real potential in this targeted genetic test.”

Comments

What To Read Next